Condition: Diabetic Foot Ulcer · Sponsor: Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.
The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.
This description comes directly from the study's public registry record.
Amanda Fu, M.D.,MBA · 3910204908 · amanda.fu@d2vclinical.com
Always discuss trial participation with your own doctor first.
| Site 001 | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06852976